Umckaloabo is commonly used by mouth for infections including bronchitis, sore throat, tonsillitis, and the common cold, but there is only limited scientific evidence to support these uses.
How does it work ?
Uses & Effectiveness ?
Possibly Effective for
- Bronchitis. Adults and children with bronchitis who start taking a specific umckaloabo extract within 48 hours of feeling sick seem to have fewer symptoms after 7 days of treatment.
- A lung disease that makes it harder to breathe (chronic obstructive pulmonary disease or COPD). Taking a specific umckaloabo extract along with standard treatment seems to reduce the number of COPD flares in people with moderate or severe COPD. Umckaloabo might also reduce COPD symptoms, the use of antibiotics during a flare, and the number of days missed from work related to COPD.
- Common cold. Some research shows that taking a specific umckaloabo extract might help reduce symptoms and clear up the common cold after 10 days of treatment. In children with asthma who have a cold, umckaloabo liquid may help improve cough and nasal symptoms.
- Sore throat and swollen tonsils (tonsillopharyngitis). When given to children experiencing sore throat and swollen tonsils, umckaloabo extract seems to reduce pain and difficulty swallowing after 4 days of treatment.
Insufficient Evidence for
- Asthma. Early research suggests that taking umckaloabo liquid three times daily for 5 days reduces asthma attacks in children with mild asthma and a cold.
- Swelling (inflammation) of the nasal cavity and sinuses (rhinosinusitis). Early research suggests that taking umckaloabo extract three times per day helps reduce symptoms and clear up inflammation after 10-21 days of treatment.
- Genital herpes.
- Cold sores (herpes labialis).
- Sore throat (pharyngitis).
- Swelling (inflammation) of the tonsils (tonsillitis).
- Other conditions.
Special Precautions and Warnings
Children: Umckaloabo is POSSIBLY SAFE when taken by mouth for up to one week. There isn't enough reliable information to know if it is safe when taken for longer periods of time.
Diseases of the immune system such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: Umckaloabo might cause the immune system to become more active. This could increase the symptoms of these diseases. If you have one of these conditions, it's best to avoid using umckaloabo.
Bleeding disorders: Umckaloabo might slow blood clotting and increase bleeding. In theory, Umckaloabo might make bleeding disorders worse.
Surgery: Umckaloabo might slow blood clotting. In theory, it might increase the risk for bleeding during surgical procedures. Stop using umckaloabo at least 2 weeks before a scheduled surgery.
Medications that decrease the immune system (Immunosuppressants) interacts with UMCKALOABO
South African geranium might increase the immune system. Taking South African geranium along with some medications that decrease the immune system might decrease the effectiveness of medications that decrease the immune system.
Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others
Be cautious with this combination
- For swelling (inflammation) of the main airways in the lung (bronchitis): 30 drops of a specific extract of umckaloabo (EPs 7630, Dr. Willmar Schwabe Pharmaceuticals) three times daily for 7 days. This same extract has also been used in tablet form as 10-30 mg three times daily for 7 days.
- For a lung disease that makes it harder to breathe (chronic obstructive pulmonary disease or COPD): 30 drops of a specific extract of umckaloabo (EPs 7630, Dr. Willmar Schwabe Pharmaceuticals) has been taken three times daily for 24 weeks.
- For common cold: 30 or 60 drops three times daily of a specific extract of umckaloabo (EPs 7630, Dr. Willmar Schwabe Pharmaceuticals) for 10 days.
- For swelling (inflammation) of the main airways in the lung (bronchitis): In children age 7-12 years, 20 drops of a specific umckaloabo extract (EPs 7630, Dr. Willmar Schwabe Pharmaceuticals) three times daily for 7 days. In children age 6 years or less, 10 drops of this extract three times daily for 7 days.
- For common cold: 5-10 drops of a specific extract of umckaloabo (EPs 7630, Dr. Willmar Schwabe Pharmaceuticals) three times daily for 5 days.
Beil, W. and Kilian, P. EPs 7630, an extract from Pelargonium sidoides roots inhibits adherence of Helicobacter pylori to gastric epithelial cells. Phytomedicine 2007;14 Suppl 6:5-8. View abstract.
Chuchalin, A. G., Berman, B., and Lehmacher, W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): a randomized, double-blind, placebo-controlled trial. Explore.(NY) 2005;1(6):437-445. View abstract.
de Boer, H. J., Hagemann, U., Bate, J., and Meyboom, R. H. Allergic reactions to medicines derived from Pelargonium species. Drug Saf 2007;30(8):677-680. View abstract.
Koch E, Lanzendörfer-Goossens Wohn C. Stimulation of interferon (IFN)-â-synthesis and natural killer (NK) cell activity by an aqueous-ethanolic extract from roots of Pelargonium sidoides (Umckaloabo). Naunyn-Schmiederberg's Arch Pharmacol 2002;365 (suppl 1):R75.
Kolodziej, H., Burmeister, A., Trun, W., Radtke, O. A., Kiderlen, A. F., Ito, H., Hatano, T., Yoshida, T., and Foo, L. Y. Tannins and related compounds induce nitric oxide synthase and cytokines gene expressions in Leishmania major-infected macrophage-like RAW 264.7 cells. Bioorg.Med Chem 12-1-2005;13(23):6470-6476. View abstract.
Lizogub, V. G., Riley, D. S., and Heger, M. Efficacy of a pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore.(NY) 2007;3(6):573-584. View abstract.
Matthys, H. and Heger, M. Treatment of acute bronchitis with a liquid herbal drug preparation from Pelargonium sidoides (EPs 7630): a randomised, double-blind, placebo-controlled, multicentre study. Curr.Med Res Opin. 2007;23(2):323-331. View abstract.
Matthys, H., Eisebitt, R., Seith, B., and Heger, M. Efficacy and safety of an extract of Pelargonium sidoides (EPs 7630) in adults with acute bronchitis. A randomised, double-blind, placebo-controlled trial. Phytomedicine 2003;10 Suppl 4:7-17. View abstract.
Schulz, V. Liquid herbal drug preparation from the root of Pelargonium sidoides is effective against acute bronchitis: results of a double-blind study with 124 patients. Phytomedicine 2007;14 Suppl 6:74-75. View abstract.
Trun, W., Kiderlen, A. F., and Kolodziej, H. Nitric oxide synthase and cytokines gene expression analyses in Leishmania-infected RAW 264.7 cells treated with an extract of Pelargonium sidoides (Eps 7630). Phytomedicine 2006;13(8):570-575. View abstract.
Wittschier, N., Lengsfeld, C., Vorthems, S., Stratmann, U., Ernst, J. F., Verspohl, E. J., and Hensel, A. Large molecules as anti-adhesive compounds against pathogens. J Pharm Pharmacol. 2007;59(6):777-786. View abstract.
Agbabiaka TB, Guo R, Ernst E. Pelargonium sidoides for acute bronchitis. A systematic review and meta-analysis. Phytomedicine 2008;15:378-85. View abstract.
Bereznoy VV, Riley DS, Wassmer G, Heger M. Efficacy of extract of Pelargonium sidoides in children with acute non-group A beta-hemolytic streptococcus tonsillopharyngitis: a randomized, double-blind, placebo-controlled trial. Altern Ther Health Med 2003;9:68-79. View abstract.
Brendler T, van Wyk BE. A historical, scientific and commercial perspective on the medicinal use of Pelargonium sidoides (Geraniaceae). J Ethnopharmacol 2008;119:420-33. View abstract.
Chuchalin AG, Berman B, Lehmacher W. Treatment of acute bronchitis in adults with a pelargonium sidoides preparation (EPs 7630): A randomized, double-blind, placebo-controlled trial. Explore 2005;1:437-45.
Conrad A, Hansmann C, Engels I, et al. Extract of Pelargonium sidoides (EPs 7630) improves phagocytosis, oxidative burst, and intracellular killing of human peripheral blood phagocytes in vitro. Phytomedicine 2007;14 Suppl 6:46-51. View abstract.
Conrad A, Jung I, Tioua D, et al. Extract of Pelargonium sidoides (EPs 7630) inhibits the interactions of group A-streptococci and host epithelia in vitro. Phytomedicine 2007;14 Suppl 6:52-9. View abstract.
Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother Res 2001;15:122-6. View abstract.
Kayser O, Kolodziej H. Antibacterial activity of extracts and constituents of Pelargonium sidoides and Pelargonium reniforme. Planta Med 1997;63:508-10. View abstract.
Koch E, Biber A. Treatment of rats with the Pelargonium sidoides extract EPs 7630 has no effect on blood coagulation parameters or on the pharmacokinetics of warfarin. Phytomedicine 2007;14 Suppl 6:40-5. View abstract.
Kolodziej H, Kayser O, Radtke OA, et al. Pharmacological profile of extracts of Pelargonium sidoides and their constituents. Phytomedicine 2003;10 Suppl 4:18-24. View abstract.
Kolodziej H, Kiderlen AF. In vitro evaluation of antibacterial and immunomodulatory activities of Pelargonium reniforme, Pelargonium sidoides and the related herbal drug preparation EPs 7630. Phytomedicine 2007;14 Suppl 6:18-26. View abstract.
Matthys H, Funk P. Pelargonium sidoides preparation EPs 7630 in COPD: health-related quality-of-life and other patient-reported outcomes in adults receiving add-on therapy. Curr Med Res Opin 2018;34(7):1245-51. View abstract.
Matthys H, Heger M. EPs 7630-solution--an effective therapeutic option in acute and exacerbating bronchitis. Phytomedicine 2007;14 Suppl 6:65-8. View abstract.
Matthys H, Kamin W, Funk P, Heger M. Pelargonium sidoides preparation (EPs 7630) in the treatment of acute bronchitis in adults and children. Phytomedicine 2007;14 Suppl 6:69-73. View abstract.
Matthys H, Lizogub VG, Malek FA, Kieser M. Efficacy and tolerability of EPs 7630 tablets in patients with acute bronchitis: a randomised, double-blind, placebo-controlled dose-finding study with a herbal drug preparation from Pelargonium sidoides. Curr Med Res Opin 2010;26:1413-22. View abstract.
Matthys H, Pliskevich DA, Bondarchuk OM, Malek FA, Tribanek M, Kieser M. Randomised, double-blind, placebo-controlled trial of EPs 7630 in adults with COPD. Respir Med 2013;107(5):691-701. View abstract.
Perić A, Gaćeša D, Barać A, Sotirović J, Perić AV. Herbal Drug EPs 7630 versus Amoxicillin in Patients with Uncomplicated Acute Bacterial Rhinosinusitis: A Randomized, Open-Label Study. Ann Otol Rhinol Laryngol. 2020;129(10):969-976. View abstract.
Riley DS, Lizogub VG, Zimmermann A, Funk P, Lehmacher W. Efficacy and tolerability of high-dose Pelargonium extract in patients with the common cold. Altern Ther Health Med 2018;24(2):16-26. View abstract.
Schapowal A, Dobos G, Cramer H, et al. Treatment of signs and symptoms of the common cold using EPs 7630 - results of a meta-analysis. Heliyon. 2019 Nov 26;5(11):e02904. View abstract.
Schnitzler P, Schneider S, Stintzing FC, et al. Efficacy of an aqueous Pelargonium sidoides extract against herpesvirus. Phytomedicine 2008;15:1108-16. View abstract.
Schotz K, Noldner M. Mass spectroscopic characterisation of oligomeric proanthocyanidins derived from an extract of Pelargonium sidoides roots (EPs 7630) and pharmacological screening in CNS models. Phytomedicine 2007;14 Suppl 6:32-9. View abstract.
Seidel V, Taylor PW. In vitro activity of extracts and constituents of Pelagonium against rapidly growing mycobacteria. Int J Antimicrob Agents 2004;23:613-9. View abstract.
Tahan F, Yaman M. Can the Pelargonium sidoides root extract EPs 7630 prevent asthma attacks during viral infections of the upper respiratory tract in children? Phytomedicine 2013;20(2):148-50. View abstract.
Teschke R, Frenzel C, Schulze J, Eickhoff A. Spontaneous reports of primarily suspected herbal hepatotoxicity by Pelargonium sidoides: was causality adequately ascertained? Regul Toxicol Pharmacol 2012;63(1):1-9. View abstract.
Teschke R, Frenzel C, Wolff A, et al. Initially purported hepatotoxicity by Pelargonium sidoides: the dilemma of pharmacovigilance and proposals for improvement. Ann Hepatol 2012;11(4):500-12. View abstract.
Timmer A, Günther J, Motschall E, Rücker G, Antes G, Kern WV. Pelargonium sidoides extract for treating acute respiratory tract infections. Cochrane Database Syst Rev 2013;(10):CD006323. View abstract.
Timmer A, Günther J, Rücker G, et al. Pelargonium sidoides extract for acute respiratory tract infections. Cochrane Database Syst Rev 2008;(3):CD006323. View abstract.
Wittschier N, Faller G, Hensel A. An extract of Pelargonium sidoides (EPs 7630) inhibits in situ adhesion of Helicobacter pylori to human stomach. Phytomedicine 2007;14:285-8. View abstract.
You Might Also Like
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2020.